Darutigenol alleviates ulcerative colitis via promoting Akkermansia muciniphila-mediated proline synthesis
Ontology highlight
ABSTRACT: Gut microbiota dysbiosis is associated with the occurrence and development of inflammatory bowel disease (IBD). Darutigenol (DL) is a natural compound with limited oral bioavailability, but has shown promise in the treatment of ulcerative colitis (UC). However, the precise mechanisms underlying its therapeutic effects remain incompletely understood. To identify the critical gut microbial species and microbial metabolites associated with the UC-protective effects of DL, we assessed its microbiota-dependent anti-UC effects through 16S rRNA sequencing, antibiotic treatment, and fecal microbiota transplantation. Metabolomics analysis, transcriptional analysis, and targeted bacteria/metabolites gavage were conducted to explore how DL regulates gut microbiota to reduce the severity of UC. The results showed that DL mainly promoted the synthesis of its metabolite proline by regulating the abundance of Akkermansia muciniphila (A. muciniphila), thereby exerting anti-UC effect. Interestingly, we discovered that DL could promote the growth of A. muciniphila in the gut by targeting IDO1. Additionally, proline supplementation exerts an anti-UC effect by downregulating the IL-17 signaling pathway. Together, our study demonstrated that DL promoted the growth of A. muciniphila by targeting IDO1 and stimulates proline production, thereby alleviating the symptoms of UC. These findings offer new insights into the anti-UC mechanisms driven by DL
INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase
PROVIDER: MTBLS10395 | MetaboLights | 2025-09-26
REPOSITORIES: MetaboLights
ACCESS DATA